Ipca Laboratories (IPCALAB) Stock Overview

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

IPCALAB Stock Information

Symbol

IPCALAB

Address

48, Kandivli Industrial EstateMumbai, 400067India

Founded

Trading hours

Website

https://www.ipca.com

Country

🇮🇳 India

Phone Number

91 22 6647 4444

Ipca Laboratories (IPCALAB) Price Chart

Ipca Laboratories Overview: Key Details and Summary

Stock data	2023	Change
Price	$16.44	N/A
Market Cap	$4.17B	N/A
Shares Outstanding	253.70M	0.00%
Employees	16.17K	N/A
Shareholder Equity	59.15B	6.76%

Valuation	2023	Change
P/E Ratio	0.89	N/A
P/S Ratio	5.64	N/A
P/B Ratio	0.07	N/A

Growth	2023	Change
Return on Equity	0.0010	N/A

Earnings	2023	Change
Revenue	$740.05M	N/A
Earnings	$57.11M	N/A
EPS	18.58	N/A
Earnings Yield	1.13	N/A
Gross Margin	0.6121	N/A
Operating Margin	0.1135	N/A
Net income margin	0.0772	N/A

Financial Strength	2023	Change
Total Assets	$1.03B	N/A
Total Debt	$176.61M	N/A
Cash on Hand	$259.35M	N/A
Debt to Equity	0.0055	21.92%
Cash to Debt	$1.47	-12.76%
Current Ratio	$2.87	-5.49%